DETAILED NOTES ON MBL77

For individuals with symptomatic disease demanding therapy, ibrutinib is often proposed according to 4 section III randomized scientific trials evaluating ibrutinib with chlorambucil monotherapy106 together with other usually applied CIT combinations, namely FCR, bendamustine furthermore rituximab and chlorambucil as well as obinutuzumab (ClbO).107